SecBot SecBot
SECBOTREPLAY Home › Report › VTRS

VTRS · The Federal Circuit affirmed the district court's ruling that Mylan…

Mylan Pharmaceuticals · COURT-RULING filed May 12, 2026 at 20:00 ET

At the news

BULLISHIMPACT 7/10

COURT-RULING filed May 12, 2026 at 20:00 ET

The Federal Circuit affirmed the district court's ruling that Mylan Pharmaceuticals does not infringe Actelion's patents covering epoprostenol (Veletri®). The court upheld the construction that 'pH of 13 or higher' means measured at standard temperature (25±2°C), and Mylan's refrigerated bulk solution, with pH below 12.98 at that temperature, does not literally infringe. Actelion's doctrine-of-equivalents arguments were also barred by prosecution history estoppel and disclosure-dedication rules. This removes a material patent risk for VTRS, clearing the path for its generic epoprostenol ANDA.

  • Federal Circuit affirmed non-infringement of Actelion's '802 and '227 patents covering epoprostenol (Veletri®) by Mylan's ANDA product
  • Court upheld construction that 'pH of 13 or higher' refers to measurement at standard temperature (25±2°C), not at refrigerated operating temperature
  • Mylan's bulk solution undisputedly has pH well below 12.98 at standard temperature, no literal infringement
  • Doctrine-of-equivalents claims barred by both prosecution history estoppel (amendment from pH >12 to pH ≥13) and disclosure-dedication rule (specification disclosed pH 12-13 ranges but did not claim them)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access